Information  X 
Enter a valid email address

EPIC/TIDM matching '0QQ6'

Date
Time Source
Company
Announcement
21 Oct 2019 6:00 am GNW   Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche’s Tecentriq in combination with Avastin increased overall survival and progression-free survival in people with unresectable hepatocellular carcinoma
18 Oct 2019 6:00 am GNW   Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche announces FDA approval of Xofluza (baloxavir marboxil) for people at high risk of developing influenza-related complications
16 Oct 2019 6:00 am GNW   Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche reports very strong sales growth in the first nine months of 2019 – outlook raised
14 Oct 2019 6:00 am GNW   Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Phase III PEMPHIX study shows Roche’s MabThera/Rituxan (rituximab) superior to mycophenolate mofetil in patients with pemphigus vulgaris
30 Sep 2019 3:30 pm GNW   Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche presents positive Phase III results for Tecentriq® (atezolizumab) in combination with platinum-based chemotherapy in people with previously untreated advanced bladder cancer
  7:30 am GNW   Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche to present results of first prospective trial using blood-based next generation sequencing which successfully identifies people for treatment with Alecensa
  6:05 am GNW   Factsheet F. Hoffmann-La Roche Ltd (0QQ6) FDA approves Roche’s Rituxan (rituximab) in children with two rare blood vessel disorders
  6:00 am GNW   Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.
28 Sep 2019 6:00 am GNW   Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche to present new and updated data at ESMO 2019 reinforcing the use of Alecensa in the first-line setting for advanced ALK-positive non-small cell lung cancer
27 Sep 2019 3:00 pm GNW   Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche's Tecentriq improves overall survival as a first-line monotherapy in certain people with advanced non-small cell lung cancer
23 Sep 2019 6:00 am GNW   Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche to present new data from its broad oncology portfolio at the European Society for Medical Oncology 2019 Congress
20 Sep 2019 6:00 am GNW   Factsheet F. Hoffmann-La Roche Ltd (0QQ6) FDA approves cobas Babesia, Roche’s first whole blood test for donor screening
19 Sep 2019 6:00 am GNW   Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche renews its commitment to the primary healthcare Phelophepa trains, marking the 25th anniversary
18 Sep 2019 6:00 am GNW   Factsheet F. Hoffmann-La Roche Ltd (0QQ6) FDA grants Breakthrough Therapy Designation for Roche’s Gazyva (obinutuzumab) in Lupus Nephritis
16 Sep 2019 8:00 am GNW   Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche ranked as one of the most sustainable healthcare companies in the Dow Jones Sustainability Indices for the eleventh year running
  6:00 am GNW   Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche receives FDA clearance for cobas pro integrated solutions designed to help labs deliver faster results to patients
13 Sep 2019 6:03 am GNW   Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche presents new 6-year OCREVUS (ocrelizumab) data which showed that earlier initiation and continuation of treatment reduced disability progression in multiple sclerosis
  6:00 am GNW   Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche’s fixed-dose subcutaneous combination of Perjeta and Herceptin showed non-inferiority when compared to intravenous formulations for people with HER2-positive breast cancer
12 Sep 2019 6:03 am GNW   Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche’s satralizumab significantly reduced relapse risk in second positive phase III study for neuromyelitis optica spectrum
  6:00 am GNW   Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche’s Tecentriq as a first-line monotherapy helped certain people with advanced non-small cell lung cancer live longer compared with chemotherapy
10 Sep 2019 6:00 am GNW   Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche presents new OCREVUS (ocrelizumab) biomarker data that increase understanding of disease progression in multiple sclerosis at ECTRIMS
06 Sep 2019 6:03 am GNW   Factsheet F. Hoffmann-La Roche Ltd (0QQ6) European Commission approves Roche’s Tecentriq in combination with chemotherapy for the initial treatment of people with extensive-stage small cell lung cancer
  6:00 am GNW   Factsheet F. Hoffmann-La Roche Ltd (0QQ6) European Commission approves Roche’s new Tecentriq-based combination therapy as an initial treatment for most common form of advanced lung cancer
04 Sep 2019 6:00 am GNW   Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche to present pivotal data for satralizumab in neuromyelitis optica spectrum disorder and six-year OCREVUS data in multiple sclerosis at ECTRIMS
03 Sep 2019 6:00 am GNW   Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.
02 Sep 2019 6:10 am GNW   Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Positive phase III results show Xofluza reduces risk of developing flu after contact with an infected person by 86%
  6:00 am GNW   Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche presents positive phase III study results for one-dose Xofluza in children with flu
29 Aug 2019 6:03 am GNW   Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche launches VENTANA PD-L1 (SP142) Assay in CE markets as first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq
  6:00 am GNW   Factsheet F. Hoffmann-La Roche Ltd (0QQ6) European Commission approves Roche’s Tecentriq in combination with Abraxane for people with PD-L1-positive, metastatic triple-negative breast cancer
16 Aug 2019 6:00 am GNW   Factsheet F. Hoffmann-La Roche Ltd (0QQ6) FDA approves Roche’s RozlytrekTM (entrectinib) for people with ROS1-positive, metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumours
05 Aug 2019 6:00 am GNW   Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche’s Tecentriq plus platinum-based chemotherapy reduced the risk of disease worsening or death in people with previously untreated advanced bladder cancer
31 Jul 2019 6:00 am GNW   Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.
26 Jul 2019 12:18 pm GNW   Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche receives CHMP positive opinion for new Tecentriq-based combination therapy as an initial treatment for most common form of advanced lung cancer
  12:15 pm GNW   Factsheet F. Hoffmann-La Roche Ltd (0QQ6) CHMP recommends EU approval of Roche’s Tecentriq in combination with chemotherapy as an initial treatment of adults with extensive-stage small cell lung cancer
25 Jul 2019 6:00 am GNW   Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche reports very strong performance in the first half of 2019 – Outlook raised
22 Jul 2019 6:00 am GNW   Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche expands the Global Access Program beyond HIV to also include diagnostic tests for Tuberculosis, Hepatitis, and Human Papillomavirus
09 Jul 2019 6:00 am GNW   Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche presents a broad range of data for Hemlibra demonstrating continued benefits for people with haemophilia A at the ISTH 2019 Congress
28 Jun 2019 11:45 am GNW   Factsheet F. Hoffmann-La Roche Ltd (0QQ6) CHMP recommends EU approval of Roche’s Tecentriq in combination with Abraxane as an initial treatment for people with PD-L1-positive, metastatic triple-negative breast cancer
18 Jun 2019 7:00 am GNW   Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Japan becomes the first country to approve Roche’s personalised medicine Rozlytrek
11 Jun 2019 6:03 am GNW   Factsheet F. Hoffmann-La Roche Ltd (0QQ6) FDA grants Roche’s Polivy accelerated approval for people with previously treated aggressive lymphoma
  6:00 am GNW   Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Changes in Roche's Board of Directors and Corporate Executive Committee
10 Jun 2019 6:00 am GNW   Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche and Spark Therapeutics, Inc. receive Request for Additional Information from FTC under Hart-Scott-Rodino Act and announce extension of tender offer for shares of Spark Therapeutics, Inc.
04 Jun 2019 4:09 pm GNW   Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Pivotal phase III CLL14 results for Venclexta/Venclyxto in combination with Gazyva/Gazyvaro for chronic lymphocytic leukaemia presented at ASCO 2019 and published in the New England Journal of Medicine
03 Jun 2019 6:00 am GNW   Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche presents data from across its breast cancer portfolio at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
02 Jun 2019 12:30 pm GNW   Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche’s Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer shows positive data in those with liver metastases
31 May 2019 6:00 am GNW   Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche and GE Healthcare launch NAVIFY Tumor Board with medical imaging capabilities to enable more personalised treatment decisions in cancer care
16 May 2019 6:03 am GNW   Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche announces FDA approval for Venclexta plus Gazyva for people with previously untreated chronic lymphocytic leukaemia
  6:00 am GNW   Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche's personalised medicine entrectinib shrank tumours harbouring NTRK, ROS1 or ALK gene fusions in children and adolescents
14 May 2019 6:03 am GNW   Factsheet F. Hoffmann-La Roche Ltd (0QQ6) New Roche test aids clinicians in accelerating tuberculosis diagnosis and treatment by detecting antimicrobial resistance within the world's leading cause of infectious disease deaths
  6:00 am GNW   Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche and Spark Therapeutics, Inc. announce expected refiling date of Premerger Notification and Report Forms under the HSR Act and extension of tender offer for shares of Spark Therapeutics, Inc.
10 May 2019 6:00 am GNW   Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche to present new data highlighting comprehensive approach to cancer care at 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
08 May 2019 6:00 am GNW   Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche to present new OCREVUS (ocrelizumab) data analyses showing significant reduction of disability progression in relapsing and primary progressive multiple sclerosis at the AAN Annual Meeting
07 May 2019 6:00 am GNW   Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche presents data from the risdiplam pivotal FIREFISH and SUNFISH studies in spinal muscular atrophy at the 2019 AAN Annual Meeting
06 May 2019 6:00 am GNW   Factsheet F. Hoffmann-La Roche Ltd (0QQ6) FDA approves Roche's Kadcyla for adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment
29 Apr 2019 6:00 am GNW   Factsheet F. Hoffmann-La Roche Ltd (0QQ6) New Roche data at the 2019 AAN Annual Meeting showcase breadth and promise of neuroscience portfolio
26 Apr 2019 6:00 am GNW   Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche and Spark Therapeutics, Inc. announce withdrawal and refiling of Premerger Notification and Report Form under the HSR Act and extension of tender offer for shares of Spark Therapeutics, Inc.
23 Apr 2019 6:00 am GNW   Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche launches new VENTANA HER2 Dual ISH companion diagnostic test for breast and gastric cancer patients eligible for targeted therapy
17 Apr 2019 6:00 am GNW   Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche reports a strong start in 2019 and raises the outlook for the full-year
03 Apr 2019 6:00 am GNW   Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche and Spark Therapeutics, Inc. announce withdrawal and refiling of Premerger Notification and Report Form under the HSR Act and extension of tender offer for shares of Spark Therapeutics, Inc.
01 Apr 2019 6:00 am GNW   Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche's ipatasertib in combination with Tecentriq and chemotherapy shows promising anti-tumour activity in triple-negative breast cancer in early phase trial


Company Announcements Archive »

 
Headlines
Top categories
Company finder
Forthcoming announcements

a d v e r t i s e m e n t